MA34923B1 - Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets - Google Patents

Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets

Info

Publication number
MA34923B1
MA34923B1 MA36205A MA36205A MA34923B1 MA 34923 B1 MA34923 B1 MA 34923B1 MA 36205 A MA36205 A MA 36205A MA 36205 A MA36205 A MA 36205A MA 34923 B1 MA34923 B1 MA 34923B1
Authority
MA
Morocco
Prior art keywords
pcsk9
antibodies
antigen
specific
treatment
Prior art date
Application number
MA36205A
Other languages
English (en)
Inventor
Corinne Hanotin
Laurence Bessac
Umesh Chaudhari
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45529125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34923(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP11305089A external-priority patent/EP2481758A1/fr
Priority claimed from EP11305088.4A external-priority patent/EP2650016A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34923B1 publication Critical patent/MA34923B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)

Abstract

La présente invention concerne des procédés pour traiter des maladies ou des affections dans lesquelles l'expression ou l'activité de proprotéine convertase subtilisine/kexine type 9 (PCSK9) a un impact par administration d'anticorps spécifiques pour PCSK9 ou de fragments de liaison d'antigène de ceux-ci et de préférence par administration additionnelle d'un inhibiteur de 3-hydroxy-3-méthyl-glutaryl-CoA réductase (HMG-CoA réductase). La présente invention concerne en outre des anticorps spécifiques pour PCSK9 ou des fragments de liaison d'antigène de ceux-ci pour utilisation dans le traitement de maladies ou affections dans lesquelles l'expression ou l'activité de PCSK9 a un impact. La présente invention concerne en outre des articles de fabrication comprenant un matériau d'emballage, des anticorps spécifiques pour PCSK9 ou des fragments de liaison d'antigène de ceux-ci, et une étiquette ou une notice d'utilisation indiquant quels groupes de patients peuvent être traités avec lesdits anticorps ou fragments, quels groupes de traitement ne doivent pas être traités avec lesdits anticorps ou fragments, et quel régime posologique doit être utilisé. La présente invention concerne en outre des procédés d'essai de l'efficacité d'anticorps spécifiques pour PCSK9 ou des fragments de liaison d'antigène de ceux-ci pour le traitement de certaines maladies ou affections et pour le traitement de sous-groupes spécifiques de patients.
MA36205A 2011-01-28 2013-08-27 Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets MA34923B1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP11305089A EP2481758A1 (fr) 2011-01-28 2011-01-28 Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers (11566)
EP11305088.4A EP2650016A1 (fr) 2011-01-28 2011-01-28 Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement basés sur des régimes de dosage particuliers (11565)
EP11305514 2011-04-29
EP11305513 2011-04-29
EP11306039 2011-08-12
EP11306040 2011-08-12
EP11306201 2011-09-22
EP11306202 2011-09-22
EP11306450 2011-11-08
EP11306449 2011-11-08
PCT/EP2012/051320 WO2012101252A2 (fr) 2011-01-28 2012-01-27 Anticorps humains contre pcsk9 pour utilisation dans des procédés de traitement de groupes particuliers de sujets

Publications (1)

Publication Number Publication Date
MA34923B1 true MA34923B1 (fr) 2014-02-01

Family

ID=45529125

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36205A MA34923B1 (fr) 2011-01-28 2013-08-27 Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets

Country Status (37)

Country Link
US (7) US9682013B2 (fr)
EP (4) EP3326648B1 (fr)
JP (8) JP2014508142A (fr)
KR (6) KR20190062612A (fr)
CN (4) CN110711248A (fr)
AR (3) AR084938A1 (fr)
AU (5) AU2012210481B2 (fr)
BR (2) BR112013018877A2 (fr)
CA (2) CA2825778A1 (fr)
CL (2) CL2013002161A1 (fr)
CO (2) CO6751277A2 (fr)
CR (1) CR20130406A (fr)
CY (1) CY1121236T1 (fr)
DK (1) DK2668212T3 (fr)
DO (1) DOP2013000170A (fr)
EC (1) ECSP13012792A (fr)
ES (3) ES2674600T3 (fr)
GT (1) GT201300186A (fr)
HR (1) HRP20180959T1 (fr)
HU (1) HUE039258T2 (fr)
IL (5) IL227658A0 (fr)
LT (1) LT2668212T (fr)
MA (1) MA34923B1 (fr)
MX (5) MX385311B (fr)
MY (2) MY176600A (fr)
NI (1) NI201300064A (fr)
PE (2) PE20181052A1 (fr)
PH (3) PH12013501576A1 (fr)
PL (3) PL3395836T3 (fr)
PT (1) PT2668212T (fr)
RS (1) RS57339B1 (fr)
RU (4) RU2603481C2 (fr)
SG (2) SG192118A1 (fr)
SI (1) SI2668212T1 (fr)
TW (3) TWI635870B (fr)
WO (3) WO2012101252A2 (fr)
ZA (2) ZA201305524B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US12269897B2 (en) 2008-12-15 2025-04-08 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US12606638B2 (en) 2013-11-12 2026-04-21 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
RU2015101113A (ru) 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения
EP2882778B1 (fr) * 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anticorps anti-pcsk9 ayant des caractéristiques de liaison dépendantes du ph
EP2703009A1 (fr) * 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2703008A1 (fr) * 2012-08-31 2014-03-05 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers
EP2706070A1 (fr) * 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
CN105142695B (zh) 2013-03-15 2020-06-02 安进公司 身体轮廓可调适的自动注射器装置
EP2968775B1 (fr) 2013-03-15 2019-12-18 Amgen Inc. Boîte à médicament, autoinjecteur et système d'autoinjecteur
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
SG11201507878SA (en) 2013-03-22 2015-10-29 Amgen Inc Injector and method of assembly
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (fr) * 2013-06-07 2014-12-10 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
KR20160024906A (ko) * 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
EP2862877A1 (fr) * 2013-10-18 2015-04-22 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
ES2901400T3 (es) * 2013-06-07 2022-03-22 Regeneron Pharma Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
CA2916259C (fr) * 2013-06-28 2024-02-20 Amgen Inc. Procedes de traitement d'une hypercholesterolemie familiale homozygote
WO2015050158A1 (fr) * 2013-10-01 2015-04-09 国立大学法人三重大学 Vaccin d'induction de lymphocytes t contenant une séquence interépitope favorisant une présentation d'antigène
PT3055333T (pt) * 2013-10-11 2020-03-11 Regeneron Pharma Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
EP3421066B1 (fr) 2013-10-24 2021-03-03 Amgen Inc. Injecteur et procédé d'assemblage
EP3060281B1 (fr) 2013-10-24 2019-01-30 Amgen Inc. Système de distribution de médicaments équipé d'un dispositif de commande sensible à la température
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015119906A1 (fr) 2014-02-05 2015-08-13 Amgen Inc. Système d'administration de médicament doté d'un générateur de champ électromagnétique
EP3104879A2 (fr) * 2014-02-14 2016-12-21 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de patients atteints d'hypercholestérolémie non correctement maîtrisée par une thérapie à la statine à dose modérée
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PL3119810T3 (pl) * 2014-03-17 2024-07-15 Sanofi Biotechnology Sposoby obniżania ryzyka sercowo-naczyniowego
US20150283236A1 (en) * 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
JP6640113B2 (ja) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド 衝撃低減要素を有する自動注入器
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送系统和使用方法
EP3169710A1 (fr) * 2014-07-14 2017-05-24 Amgen Inc. Formulations d'anticorps cristallins
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
JP6912374B2 (ja) * 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
WO2016061220A2 (fr) 2014-10-14 2016-04-21 Amgen Inc. Dispositif d'injection de médicament comportant des témoins visuels et sonores
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (fr) 2014-12-19 2021-07-14 Amgen Inc. Dispositif d'administration de médicament comportant un capteur de proximité
CA2976935C (fr) 2015-02-17 2020-03-10 Amgen Inc. Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
WO2016138434A1 (fr) 2015-02-27 2016-09-01 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CN107531798B (zh) 2015-03-20 2022-02-18 奥胡斯大学 Pcsk9的抑制剂用于脂蛋白代谢病症的治疗
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
US10548974B2 (en) * 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
CN107406511B (zh) 2015-12-31 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3401336A4 (fr) 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-pcsk9, fragment de liaison à l'antigène associé et application médicale associée
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3415159B1 (fr) 2016-02-08 2023-12-13 Mie University Médicament de prétraitement pour thérapie par perfusion de lymphocytes t pour tumeur résistante aux inhibiteurs de point de contrôle immunitaire
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (fr) 2016-05-02 2017-11-09 Amgen Inc. Adaptateur de seringue et guide pour remplir un injecteur sur le corps
EP3455142B1 (fr) 2016-05-13 2023-08-09 Amgen Inc. Ensemble manchon de flacon
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018004842A1 (fr) 2016-07-01 2018-01-04 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
WO2018034784A1 (fr) 2016-08-17 2018-02-22 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement.
EP3525820A4 (fr) * 2016-10-17 2020-09-16 Vanderbilt University Anticorps contre le virus respiratoire syncytial humain et leurs méthodes d'utilisation
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018136398A1 (fr) 2017-01-17 2018-07-26 Amgen Inc. Dispositifs d'injection et procédés d'utilisation et d'assemblage associés
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
CA3050927A1 (fr) 2017-03-06 2018-09-13 Brian Stonecipher Dispositif d'administration de medicaments dote d'une fonction de prevention d'activation
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
EP3592404A1 (fr) 2017-03-09 2020-01-15 Amgen Inc. Mécanisme d'insertion pour dispositif d'administration de médicament
KR102651078B1 (ko) 2017-03-28 2024-03-22 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (fr) 2017-07-21 2020-05-27 Amgen Inc. Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (fr) 2017-08-18 2019-02-21 Amgen Inc. Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (fr) 2017-10-04 2019-04-11 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (fr) 2017-11-03 2019-05-09 Amgen Inc. Systèmes et approches pour stériliser un dispositif d'administration de médicament
IL273664B1 (en) 2017-11-06 2026-02-01 Amgen Inc Full-fledged assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
EP3762026B1 (fr) * 2018-03-06 2026-04-08 Sanofi Biotechnology Utilisation d'inhibiteur de pcsk9 pour réduire le risque cardiovasculaire
IL278710B2 (en) * 2018-05-16 2025-09-01 Lib Therapeutics Llc Compositions comprising pcsk9 binding compounds and methods of use
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
WO2020023451A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
CA3103681A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de medicaments
EP3829692A1 (fr) 2018-07-31 2021-06-09 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de médicament
EP3856284A1 (fr) 2018-09-24 2021-08-04 Amgen Inc. Systèmes et procédés de dosage interventionnel
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US20220087901A1 (en) * 2019-02-12 2022-03-24 Amgen Inc. Systems and approaches for drug delivery device reconstitution
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2020236670A1 (fr) 2019-05-17 2020-11-26 Regeneron Pharmaceuticals, Inc. Procédés basés sur le génome pour réduire le risque cardiovasculaire
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
EP4045109A1 (fr) * 2019-10-18 2022-08-24 Amgen Inc. Systèmes et approches pour la reconstitution d'un dispositif d'administration de médicament
JP2021041262A (ja) * 2020-12-17 2021-03-18 株式会社三洋物産 遊技機
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
WO2026030152A1 (fr) 2024-07-29 2026-02-05 Amgen Inc. Système et procédé d'évaluation de la transférabilité d'une recette de remplissage

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
CA1341152C (fr) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Proteine du recepteur du facteur d'induction des cellules humaines b2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993000807A1 (fr) 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
DE69333928T2 (de) 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
CA2147466A1 (fr) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Antagonistes du recepteur de l'interleukine-6
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
AU704723B2 (en) 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
DK0811384T3 (da) 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
JP2000509018A (ja) 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
PT923941E (pt) 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE69900746T2 (de) 1998-01-30 2002-08-14 Scios Inc., Mountain View Gesteuerte verabreichung von peptiden oder proteinen
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
EP1067182A3 (fr) 1999-07-08 2001-11-21 Helix Research Institute Proteine secretoire ou proteine de membrane
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
WO2001027116A2 (fr) 1999-10-07 2001-04-19 Eli Lilly And Company Composes et procedes permettant d'inhiber la mrp1
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
AU2001290846B2 (en) 2000-09-08 2006-02-02 Massachusetts Institute Of Technology G-CSF analog compositions and methods
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
EP1471152A1 (fr) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
DE602005020743D1 (de) 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
US20110313024A1 (en) 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005316405A1 (en) 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
KR20080071192A (ko) 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
DK2021472T3 (da) 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af genekspression
ES2366973T3 (es) 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimiento para modular la expresión génica.
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2083860A4 (fr) 2006-11-07 2010-05-26 Merck Sharp & Dohme Antagonistes de pcsk9
WO2008057459A2 (fr) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
EP2106261A4 (fr) 2006-11-07 2010-05-26 Merck Sharp & Dohme Antagonistes de pcsk9
CN101589143A (zh) 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
EP2455471A3 (fr) 2006-11-27 2012-09-12 Isis Pharmaceuticals, Inc. Procédés pour traiter l'hypercholestérolémie
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP5100101B2 (ja) 2006-12-12 2012-12-19 キヤノン株式会社 画像形成装置
BRPI0810551A2 (pt) 2007-04-13 2019-09-03 Novartis Ag moléculas e métodos para modulação da pró-proteína convertase subtilisina/quexina tipo 9 (pcsk9)
EP2152752B1 (fr) 2007-05-15 2017-11-08 F. Hoffmann-La Roche AG Anticorps dirigé contre des récepteurs couplés à la protéine g (gpcr)
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009042765A1 (fr) 2007-09-25 2009-04-02 The Regents Of The University Of California Procédés de modulation de la prokinéticine 2 dans le traitement de la réponse au stress et des troubles associés à l'angoisse
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
KR20100091191A (ko) 2007-10-26 2010-08-18 쉐링 코포레이션 항-ｐｃｓｋ9, 및 지질 및 콜레스테롤 질환의 치료 방법
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP2275443B1 (fr) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
BRPI0918419A2 (pt) 2008-09-19 2015-11-24 Hoffmann La Roche nova formulação anticorpo
CA2736864C (fr) 2008-09-19 2020-10-13 Pfizer Inc. Composition, liquide et stable, a base d'anticorps
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20100216667A1 (en) 2008-12-17 2010-08-26 Meyer Brian K Method for determining compatibility of an active pharmaceutical ingredient with materials
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
AU2010260148A1 (en) 2009-06-15 2012-02-02 Alnylam Pharmaceuticals, Inc. Lipid formulated dsRNA targeting the PCSK9 gene
CA2764180A1 (fr) 2009-06-18 2010-12-23 Wyeth Llc Formulations lyophilisees pour agents immunopharmaceutiques modulaires de petite taille
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011028938A1 (fr) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
WO2011037791A1 (fr) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
EP2483682A1 (fr) 2009-10-02 2012-08-08 INSERM - Institut National de la Santé et de la Recherche Médicale Combinaison de facteurs de risque cardiovasculaire lp(a) et d'activité de spla2 pour le diagnostic/pronostic d'une maladie/d'un événement cardiovasculaire
IN2012DN03824A (fr) 2009-10-30 2015-08-28 Merck Sharp & Dohme
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
DE102010024698A1 (de) 2010-06-23 2011-12-29 Eads Deutschland Gmbh Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US9518132B2 (en) * 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
BR112013015687A2 (pt) 2010-12-22 2016-10-11 Genentech Inc anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
KR20140006022A (ko) 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
CA3021845C (fr) 2011-04-20 2022-03-29 Amgen Inc. Appareil auto-injecteur
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012168491A1 (fr) 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
CA2746171C (fr) 2011-07-13 2018-11-06 William Jani Bouchon de fracturation recuperable
BR112014000392A2 (pt) 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
AU2013229613B2 (en) 2012-03-08 2015-07-30 F. Hoffmann-La Roche Ag Abeta antibody formulation
EP2839037B1 (fr) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarqueurs permettant d'identifier des patients qui réagiront à un traitement, et traitement desdits patients
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
KR20150059638A (ko) 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
EP2882778B1 (fr) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anticorps anti-pcsk9 ayant des caractéristiques de liaison dépendantes du ph
EP2703009A1 (fr) * 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2703008A1 (fr) 2012-08-31 2014-03-05 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers
EP2706070A1 (fr) 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
RU2538801C2 (ru) 2013-02-07 2015-01-10 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
EP3068803B1 (fr) 2013-11-12 2021-01-20 Sanofi Biotechnology Schémas posologiques pour l'utlisation d' inhibiteurs de la pcsk9
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP3104879A2 (fr) 2014-02-14 2016-12-21 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de patients atteints d'hypercholestérolémie non correctement maîtrisée par une thérapie à la statine à dose modérée
PL3119810T3 (pl) 2014-03-17 2024-07-15 Sanofi Biotechnology Sposoby obniżania ryzyka sercowo-naczyniowego
US20150283236A1 (en) 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
CN107206068A (zh) 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
JP6912374B2 (ja) 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
TW202310872A (zh) 2017-06-09 2023-03-16 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
EP3762026B1 (fr) 2018-03-06 2026-04-08 Sanofi Biotechnology Utilisation d'inhibiteur de pcsk9 pour réduire le risque cardiovasculaire

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269897B2 (en) 2008-12-15 2025-04-08 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US12612466B2 (en) 2011-07-28 2026-04-28 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US12606638B2 (en) 2013-11-12 2026-04-21 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

Also Published As

Publication number Publication date
EP2668212A2 (fr) 2013-12-04
SG192118A1 (en) 2013-09-30
PH12013501577A1 (en) 2013-09-30
JP6730388B2 (ja) 2020-07-29
AU2019229366B2 (en) 2021-09-16
MX2019008245A (es) 2019-09-06
MX385311B (es) 2025-03-18
MX366458B (es) 2019-07-10
ES2873273T3 (es) 2021-11-03
HRP20180959T1 (hr) 2018-07-27
BR112013018740A2 (pt) 2019-01-08
IL282219B (en) 2022-03-01
AU2012210481B2 (en) 2017-05-18
TW201242613A (en) 2012-11-01
KR20200133826A (ko) 2020-11-30
US9682013B2 (en) 2017-06-20
IL227658A0 (en) 2013-09-30
NZ792724A (en) 2024-07-05
US12083176B2 (en) 2024-09-10
KR20140012075A (ko) 2014-01-29
ES2674600T3 (es) 2018-07-02
ZA201305524B (en) 2014-03-26
RU2013139736A (ru) 2015-03-10
CO6751277A2 (es) 2013-09-16
LT2668212T (lt) 2018-07-10
RU2013139727A (ru) 2015-03-10
NZ613867A (en) 2015-09-25
SI2668212T1 (en) 2018-08-31
RU2604139C2 (ru) 2016-12-10
WO2012101251A1 (fr) 2012-08-02
AR084939A1 (es) 2013-07-10
HK1255729A1 (en) 2019-08-23
EP3326648B1 (fr) 2021-03-10
ECSP13012792A (es) 2013-09-30
AU2017216546B2 (en) 2019-10-03
US20190343719A1 (en) 2019-11-14
NI201300064A (es) 2013-12-17
CN103476797A (zh) 2013-12-25
SG192117A1 (en) 2013-08-30
US11246925B2 (en) 2022-02-15
AU2017216546A1 (en) 2017-09-07
DK2668212T3 (en) 2018-07-02
BR112013018877A2 (pt) 2016-10-04
AU2012210480B2 (en) 2017-05-18
JP2014508142A (ja) 2014-04-03
IL266682B (en) 2021-04-29
EP3395836B1 (fr) 2021-04-28
WO2012101253A1 (fr) 2012-08-02
IL227657A0 (en) 2013-09-30
KR20190062612A (ko) 2019-06-05
PT2668212T (pt) 2018-06-28
JP2020172514A (ja) 2020-10-22
AU2012210481A1 (en) 2013-08-22
AU2019229366A1 (en) 2019-10-03
RS57339B1 (sr) 2018-08-31
GT201300186A (es) 2014-04-29
IL265707A (en) 2019-05-30
CY1121236T1 (el) 2020-05-29
CN103476796A (zh) 2013-12-25
JP2024138473A (ja) 2024-10-08
US20140154262A1 (en) 2014-06-05
NZ613870A (en) 2015-12-24
KR20220136466A (ko) 2022-10-07
PL2668212T3 (pl) 2018-08-31
CL2013002161A1 (es) 2014-03-28
KR20140006013A (ko) 2014-01-15
PL3395836T3 (pl) 2021-12-13
MY176600A (en) 2020-08-18
TW201711698A (zh) 2017-04-01
US9561155B2 (en) 2017-02-07
PL3326648T3 (pl) 2021-10-11
JP2017095491A (ja) 2017-06-01
EP3395836A1 (fr) 2018-10-31
JP2018203772A (ja) 2018-12-27
MX2013008669A (es) 2013-10-01
PE20181052A1 (es) 2018-07-03
MX347602B (es) 2017-05-03
RU2016142277A3 (fr) 2020-03-06
AU2012210480A1 (en) 2013-08-22
DOP2013000170A (es) 2013-11-30
CN107899010A (zh) 2018-04-13
CN110711248A (zh) 2020-01-21
CA2825838C (fr) 2020-10-27
ZA201305565B (en) 2016-01-27
RU2016142277A (ru) 2018-12-17
CA2825778A1 (fr) 2012-08-02
RU2721279C2 (ru) 2020-05-18
CL2013002162A1 (es) 2014-02-21
US20170266079A1 (en) 2017-09-21
PE20140372A1 (es) 2014-03-24
IL266682A (en) 2019-07-31
JP2022141869A (ja) 2022-09-29
AR084938A1 (es) 2013-07-10
EP3326648A1 (fr) 2018-05-30
US20170340515A1 (en) 2017-11-30
PH12021500018A1 (en) 2021-12-13
CR20130406A (es) 2013-10-09
HUE039258T2 (hu) 2018-12-28
KR20190090055A (ko) 2019-07-31
TWI635870B (zh) 2018-09-21
AU2017216547A1 (en) 2017-09-07
CO6751276A2 (es) 2013-09-16
TWI625127B (zh) 2018-06-01
WO2012101252A3 (fr) 2012-11-15
US20250064926A1 (en) 2025-02-27
EP2668211A1 (fr) 2013-12-04
ES2882570T3 (es) 2021-12-02
WO2012101252A2 (fr) 2012-08-02
MY165159A (en) 2018-02-28
EP2668212B1 (fr) 2018-03-21
MX2013008672A (es) 2013-10-01
US20140178402A1 (en) 2014-06-26
CA2825838A1 (fr) 2012-08-02
RU2603481C2 (ru) 2016-11-27
JP2017095490A (ja) 2017-06-01
JP6375113B2 (ja) 2018-08-15
IL227657B (en) 2019-05-30
MX367075B (es) 2019-08-05
RU2016142273A (ru) 2018-12-18
JP2014511361A (ja) 2014-05-15
US20220218823A1 (en) 2022-07-14
PH12013501576A1 (en) 2013-09-30
JP7140800B2 (ja) 2022-09-21
TW201242614A (en) 2012-11-01
IL282219A (en) 2021-05-31
AR084937A1 (es) 2013-07-10

Similar Documents

Publication Publication Date Title
PH12021500018A1 (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
MA35800B1 (fr) Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
MX375672B (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9.
MX2024004495A (es) Agentes de acidos ribonucleicos de interferencia para usarse en la prevencion de eventos cardiovasculares.
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
WO2015073494A8 (fr) Schémas posologiques pour une utilisation avec des inhibiteurs de pcsk9
EP4252857A3 (fr) Procédés pour réduire les niveaux de lipoprotéine(a) par l'administration d'un inhibiteur de la proprotéine convertase subtilisine kexine 9 (pcsk9)
Zhao et al. Mycobacterium tuberculosis proteases and implications for new antibiotics against tuberculosis
TN2013000322A1 (en) Pharmaceutical compositions comprising human antibodies to pcsk9
Nørholt et al. Analgesic efficacy with rapidly absorbed ibuprofen sodium dihydrate in postsurgical dental pain: results from the randomized QUIKK trial.
TH158830A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยแอนติบอดีต้าน pcsk9
Sagadevan Investigation of anticancer activity and mechanisms of Meso-2, 3-dimercaptosuccinic acid (DMSA) in glioblastoma cell lines
TH177074A (th) แอนติบอดีมนุษย์ต้าน pcsk9 สำหรับใช้ในวิธีการรักษาเฉพาะกลุ่มของผู้ป่วย
EA201201529A1 (ru) Комбинация ингибиторов ксантиноксидазы и статинов и ее применение
WO2014036105A3 (fr) Inhibiteurs de clivage de la mémapsine 2 pour le traitement de la maladie d'alzheimer
Qiu et al. Fibrin (ogen) olytic Activity of Bee Venom Serine Protease
Gosch Are statins of value in therapy of osteoporosis?
MA38625B1 (fr) Procédé pour la préparation d'érythrocytes chargés d'une ou plusieurs substances d'intérêt pharmaceutique, et érythrocytes ainsi obtenus
TH161998A (th) แอนติบอดีต่อ pcsk9 และการใช้ของมัน